文献速递心脑血管急症重症综合管理与镇静镇痛

蛋白质组学富集的预测模型用于心脏骤停幸存者不良神经预后

Proteomics-Enriched Prediction Model for Poor Neurologic Outcome in Cardiac Arrest Survivors.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论在院外心脏骤停幸存者中,将α-烯醇化酶、14-3-3蛋白ζ/δ、cofilin-1和热休克同源71 kDa蛋白加入多标志物模型可显著改善不良神经预后预测(C-index 0.70)。

该前瞻性单中心研究纳入96例院外心脏骤停幸存者,以脑功能分类评分≥3定义不良神经预后。通过三步蛋白质组学策略从299种蛋白中筛选出α-烯醇化酶、14-3-3蛋白ζ/δ、cofilin-1和热休克同源71 kDa蛋白四种新生物标志物。将这些标志物与既往已知危险因素整合为临床多标志物模型后,不良神经预后预测显著改善(C-index 0.70,解释变异度11.9%,添加价值P=0.019)。63例(66%)患者出现不良神经预后。

要点

  • 在96例院外心脏骤停幸存者中,63例(66%)脑功能分类评分≥3,即不良神经预后。
  • 从299种蛋白中鉴定出α-烯醇化酶、14-3-3蛋白ζ/δ、cofilin-1和热休克同源71 kDa蛋白四种新生物标志物。
  • 将四种标志物加入包含既往已知危险因素的多标志物模型,预测不良神经预后的C-index为0.70,解释变异度11.9%,添加价值P=0.019。
  • 每种蛋白质组学鉴定的标志物均优于当前风险分层模型,并可能反映脑缺血过程中的重要病理生理通路。

适用人群与场景

  • 院外心脏骤停幸存者,前瞻性纳入96例,来自大学附属三级医疗中心。

诊断标准与关键阈值

  • 不良神经预后定义为脑功能分类评分≥3。

研究设计与关键结果

  • 前瞻性单中心研究,纳入96例院外心脏骤停幸存者,无干预。
  • 63例(66%)患者脑功能分类评分≥3(不良神经预后)。
  • 通过三步蛋白质组学策略(鸟枪法预筛选、脑组织样本交叉核对、靶向蛋白质组学验证)从299种蛋白中鉴定出α-烯醇化酶、14-3-3蛋白ζ/δ、cofilin-1和热休克同源71 kDa蛋白为不良神经预后的新生物标志物。
  • 将四种标志物加入包含既往已知危险因素的临床多标志物模型,不良神经预后预测显著改善:C-index 0.70,解释变异度11.9%,添加价值P=0.019。

证据类型、等级与局限

  • 证据类型:前瞻性单中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,将α-烯醇化酶、14-3-3蛋白ζ/δ、cofilin-1和热休克同源71 kDa蛋白与既往已知危险因素一起纳入多标志物预测模型,可显著改善院外心脏骤停幸存者的神经预后预测。
  • 作者认为,每种蛋白质组学鉴定的生物标志物均优于当前风险分层模型,并可能反映脑缺血过程中的重要病理生理通路。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Neurologic outcome prediction in out-of-hospital cardiac arrest survivors is highly limited due to the lack of consistent predictors of clinically relevant brain damage. The present study aimed to identify novel biomarkers of neurologic recovery to improve early prediction of neurologic outcome.

DESIGN: Prospective, single-center study, SETTING:: University-affiliated tertiary care center.

PATIENTS: We prospectively enrolled 96 out-of-hospital cardiac arrest survivors into our study.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Neurologic outcome was assessed by the Cerebral Performance Categories score. To identify plasma biomarkers for poor neurologic outcome (Cerebral Performance Categories score ≥ 3), we performed a three-step proteomics strategy of preselection by shotgun analyses, crosschecking in brain tissue samples, and verification by targeted proteomic analyses using a multistep statistical modeling approach. Sixty-three patients (66%) had a poor neurologic outcome. Out of a total of 299 proteins, we identified α-enolase, 14-3-3 protein ζ/δ, cofilin-1, and heat shock cognate 71 kDa protein as novel biomarkers for poor neurologic outcome. The implementation of these biomarkers into a clinical multimarker model, consisting of previously identified covariates associated to outcome, resulted in a significant improvement of neurologic outcome prediction (C-index, 0.70; explained variation, 11.9%; p for added value, 0.019).

CONCLUSIONS: This study identified four novel biomarkers for the prediction of poor neurologic outcome in out-of-hospital cardiac arrest survivors. The implementation of α-enolase, 14-3-3 protein ζ/δ, cofilin-1, and heat shock cognate 71 kDa protein into a multimarker predictive model along with previously identified risk factors significantly improved neurologic outcome prediction. Each of the proteomically identified biomarkers did not only outperform current risk stratification models but may also reflect important pathophysiologic pathways undergoing during cerebral ischemia.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Distelmaier K, Muqaku B, Wurm R, et al. Proteomics-Enriched Prediction Model for Poor Neurologic Outcome in Cardiac Arrest Survivors. Crit Care Med. 2020. PMID: 31939784. doi:10.1097/CCM.0000000000004105

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。